Investigators provide an outlook into next-generation bispecific antibodies (bsAbs) in earlier stages of development, including trispecifics, bsAb prodrugs, bsAbs that induce degradation of tumour targets and bsAbs acting as cytokine mimetics.
[Nature Reviews Drug Discovery]
